Checking endoscopy follow-up after removal of early esophageal adenocarcinoma
Tests the safety of endoscopic follow-up after removing early esophageal adenocarcinoma.
Key facts
- Who runs it
- Amsterdam UMC
- Where
- Australia, Belgium, Germany, Netherlands, Switzerland, and United Kingdom20 sites in 6 countriesChoose a country to see its sites
- Trial code
- Registry title
- Prospective Endoscopic Follow-up of Patients With Submucosal and High Risk Mucosal Esophageal Adenocarcinoma
- Status
- Recruiting
- People taking part
- 225 people, planned
- Started
- 25 Jul 2017
- Expected to end
- 25 Jul 2028
- Type of study
- Interventional
- Treatments tested
- Endoscopic follow-up
- Record updated
- 24 July 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose early cancer of the lower food pipe (esophageal adenocarcinoma) was removed through an endoscope. It checks whether follow-up with regular endoscopy alone is safe.
- Age
- 18 Years and older
- Sex
- All sexes
- Disease stage
- Submucosal (T1b) or high-risk mucosal (T1a) esophageal adenocarcinoma, with no spread to lymph nodes or other organs (N0M0).
- Earlier treatment
- The tumor must have been removed by endoscopic resection (ER). An expert GI pathologist must confirm the diagnosis in the removed tissue.
Main reasons for not taking part
- Earlier history of high-risk mucosal or deeper (≥T1sm) cancer
- Squamous cell cancer of the food pipe at the same time
- Suspected spread to lymph nodes or distant organs on scans done six weeks after ER
- Cancer cells found at the deep edge of the removed tissue (R1)
- Unable to give signed informed consent
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Patients with submucosal or high-risk mucosal EAC diagnosed in an ER specimen, by an expert gastrointestinal (GI) pathologists
- Signed informed consent
Who cannot take part
- Prior history of high-risk mucosal or ≥T1sm
- Tumor-positive deep resection margin (R1) in ER specimen
- Synchronous esophageal squamous cell carcinoma
- Suspicion on lymph node metastasis or distant metastasis on EUS, ultrasound of the neck or CT-thorax-abdomen performed six weeks after ER during baseline measurement
- Patients unable to give signed informed consent
This trial has no sites in United States.
It has sites in 6 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
Aim of this prospective multicenter study is to evaluate the safety of an endoscopic follow-up strategy in patients treated with endoscopic resection (ER) for submucosal or high-risk mucosal esophageal adenocarcinoma (T1bN0M0 or HR T1aN0M0 EAC).
The group in the trial
- Endoscopic follow-upTreatment being tested
Patients treated with endoscopic resection (ER) for a submucosal or high-risk mucosal esophageal adenocarcinoma without lymphnode- or distant metastases (N0M0) will undergo endoscopic follow-up.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Endoscopic Management of Patients With High Risk T1a and T1b N0M0 Esophageal Adenocarcinoma: a Prospective Multicenter Registry.
- Plain-language title
- Checking endoscopy follow-up after removal of early esophageal adenocarcinomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 24 July 2024